Send to

Choose Destination
Lancet. 1990 Feb 24;335(8687):434-7.

Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF.

Author information

Department of Haematology, Faculty of Clinical Sciences, University College and Middlesex School of Medicine, London, UK.


In 4 out of 16 patients receiving recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) in phase I/II studies antibodies developed to the recombinant protein. The antibodies react with sites on the native protein backbone which are normally protected by O-linked glycosylation but which are exposed in rhGM-CSF produced in yeast and Escherichia coli. Antigenicity of recombinant human proteins due to non glycosylation may have relevance to the choice of host system for production of factors for clinical use.

Comment in

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center